ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, c-Abl inhibitors are safe drugs that are well tolerated, with mild secondary effects already approved by the FDA for the treatment of chronic myeloid leukemia and another kind of cancers.